由于全球锌矿产量增加较为确定，市场对于锌价走势的预期普遍偏空，叠加贸易争端一度激化拖累，今 年以来沪锌重心震荡下移。不过前期冶炼厂利润不足且二季度检修较多，国内精炼锌产量并未出现大幅 增加一幕，社会库存持续低位，现实表现不算弱势，可以看到期价几次触及21600一线附近后都有反 弹。然而进入6月份冶炼厂产量将有明显提升，沪锌会继续向下寻找支撑吗？ 贸易争端整体缓和 地缘风险扰动增加 4月美国超预期的对等关税落地，叠加其他国家纷纷反制，工业品一度重挫，不过美国对外关税政策显 然是雷声大雨点小，历经谈判过后对多国的关税税率都出现明显下调，市场情绪随之缓和。当前时间仍 处于美国关税缓冲期当中，目前市场仍在衡量关税对于美国经济的冲击，由于对关税政策可能推高通胀 的担忧存在，美联储6月议息会议传递偏鹰态度，后续仍需关注关税缓冲期过后特朗普政府的态度变化 和年内美联储降息节奏。 最近中东地缘政治局势一度紧张，一定程度推升市场避险情绪，原油系和贵金属都出现剧烈波动，对其 余金属的影响相对有限，但对锌市则带来两个方面的担忧。一方面，近几年伊朗锌矿对华都有出口， 2024年全年进口量在8万吨附近，占国内总进口的2%附近，冲突的加 ...

FS KKR Capital (FSK) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Speaker0 Good morning, ladies and gentlemen. Welcome to FS KKR Capital Corp. First Quarter twenty twenty five Earnings Conference Call. Your lines will be in a listen only mode during the remarks by FSK's management. At the conclusion of the company's remarks, we will begin the question and answer session, at which time I will give you instructions on entering the queue. Please note that this conference is being recorded. At this time, Anna ...

Blue Bird (BLBD) Q2 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Mark Benfield - Executive Director of Profitability & Investor RelationsJohn Wyskiel - President, CEO & DirectorRazvan Radulescu - Chief Financial Officer Conference Call Participants Michael Shlisky - Managing Director & Senior Equity Research AnalystEric Stine - Senior Research AnalystTyler DiMatteo - Equity Research AnalystCraig Irwin - Managing Director, Senior Research AnalystChris Pierce - Senior Analyst Operator This ...

Financial Data and Key Metrics Changes - Revenue for Q3 FY 2025 was $113 million, up 12% year-over-year and up 14% on a constant currency basis [16] - Adjusted EBITDA for the quarter was $6 million, compared to $1.1 million in the prior year, driven by higher volume, pricing, and operational improvements [8][19] - Operating income for the quarter was $1 million, compared to an operating loss of $4.6 million from the prior year [19] Business Line Data and Key Metrics Changes - Product revenue for Q3 was $57 million, up 16% year-over-year, reflecting a 23% increase in unit volume [17] - Service revenue for the quarter was $56 million, up 9% year-over-year [17] - The service business represented approximately 49% of total revenue and 59% of gross margin for the quarter [8] Market Data and Key Metrics Changes - Book to bill ratio was over 1.2, indicating healthy customer demand across both developed and emerging markets [9] - Approximately 35% of order growth was driven by the replacement of aged equipment [9] - The company reported a backlog of approximately $452 million, with zero order cancellations in the quarter [18] Company Strategy and Development Direction - The company aims to be the most reliable global partner in radiation therapy treatment technology, focusing on operational efficiency and customer partnerships [6][7] - Investments in ERP and talent are expected to enhance adaptability and capabilities in a rapidly changing global market [7] - The service business is anticipated to be a growth engine and primary catalyst for expanding margins [10] Management's Comments on Operating Environment and Future Outlook - Management noted lower visibility on near-term growth in revenues and earnings due to global trade circumstances [5] - Despite challenges, management expressed confidence in emerging stronger and more resilient from the current environment [6] - The company expects a potential negative impact of $10 million to $15 million in Q4 revenue due to tariffs, primarily affecting product sales in China [12][21] Other Important Information - The company is exploring various mitigation actions to offset tariff impacts, including establishing a foreign trade zone and developing secondary domestic sources [11] - Total cash and cash equivalents amounted to $79 million, up from $64 million at the end of the last quarter [20] Q&A Session Summary Question: Impact of deferred China adjusted EBITDA - Management confirmed that product margins were affected by higher margin deferral on China, with product margins at 22.7% for the quarter [26][27] Question: Potential impact in markets like India and South America - Management indicated that while the China impact is significant, they see strength in other regions, including India and non-China APAC markets [28][29] Question: Scenarios regarding tariff exemptions for medical products in China - Management is working closely with their China JV to seek a tariff exemption but noted uncertainty regarding the timeline and probability of success [31][34] Question: Future activity in China and potential impacts - Management stated that they are conducting internal scenario planning and will provide more clarity in future calls [38] Question: Focus on emerging markets - Management confirmed a strategic focus on both developed and emerging markets, leveraging opportunities in regions like the UK and non-China APAC [39][41]